Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting pharmacokinetics, safety, and antiviral activity of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-table…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen (E/C/F/TAF STR) (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-05-24